GlassScriptPhysician profile
Brandon M Workman
NPI 1891012233
$2,600.10
in general payments reported to CMS, 2019-2025
14 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $404 · 2021: $776 · 2022: $828 · 2024: $16.08 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $725.61 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $706.46 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $317.32 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $211.01 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $140.51 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $123.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.08 | 2025 | Cobenfy |
| Neuronetics, INC. | $82.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $61.46 | 2022-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $48.03 | 2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $22.43 | 2022 | |
| Corium, LLC | $21.19 | 2022 | |
| Lilly USA, LLC | $16.08 | 2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.